Page 30 - Read Online

Feng et al. Hepatoma Res 2021;7:3 I http://dx.doi.org/10.20517/2394-5079.2020.107 Page 11 of 15

19 GPC3-T2-CAR-T cells for Recruiting Hepatocellular Biological: GPC3 and/or https://ClinicalTrials.gov/
immunotherapy of cancer with Carcinoma, et al. TGF-beta targeting CAR-T show/NCT03198546
GPC3 expression cells
20 NKG2D CAR-T(KD-025) in the Not yet Solid Drug: KD-025 CAR-T cells https://ClinicalTrials.gov/
treatment of relapsed or refractory recruiting Tumor|Hepatocellular show/NCT04550663
NKG2DL+ tumors Carcinoma, et al.
21 GPC3-CAR-T Cells for the Not yet Hepatocellular Biological: GPC3-CAR-T https://ClinicalTrials.gov/
hepatocellular carcinoma recruiting Carcinoma cells show/NCT04506983
22 CAR-T cell immunotherapy for Withdrawn GPC3 Positive Biological: CAR-T cell https://ClinicalTrials.gov/
HCC targeting GPC3 Hepatocellular immunotherapy show/NCT02723942
Carcinoma
23 Clinical Study on the efficacy and Unknown Primary Hepatocellular Biological: c-Met/PD-L1 https://ClinicalTrials.gov/
safety of c-Met/PD-L1 CAR-T cell status Carcinoma CAR-T cell injection show/NCT03672305
injection in the treatment of HCC
24 A study of GPC3 redirected Unknown Carcinoma, Drug: TAI-GPC3-CART cells https://ClinicalTrials.gov/
autologous T cells for advanced status Hepatocellular show/NCT02715362
HCC
25 GPC3-targeted CAR-T cell for Recruiting Hepatocellular Biological: CAR-T cell https://ClinicalTrials.gov/
treating GPC3 positive advanced Carcinoma immunotherapy show/NCT04121273
HCC
26 A Study of GPC3-targeted T Unknown Carcinoma, Drug: GPC3-CART cells https://ClinicalTrials.gov/
cells by intratumor injection for status Hepatocellular show/NCT03130712
advanced HCC (GPC3-CART)
27 Phase I/II study of anti-Mucin1 Unknown Hepatocellular Biological: anti-MUC1 CAR https://ClinicalTrials.gov/
(MUC1) CAR T cells for patients status Carcinoma, et al. T cells show/NCT02587689
with MUC1+ advanced refractory
solid tumor
28 Anti-GPC3 CAR T for treating Completed Hepatocellular Biological: anti-GPC3 CAR https://ClinicalTrials.gov/
patients with advanced HCC Carcinoma T show/NCT02395250
29 Anti-GPC3 CAR-T for treating Unknown Hepatocellular Biological: retroviral vector- https://ClinicalTrials.gov/
GPC3-positive advanced status Carcinoma transduced autologous show/NCT03084380
hepatocellular carcinoma (HCC) T cells to express anti-
GPC3 CARs|drug:
fludarabine|drug:
cyclophosphamide
30 Clinical study of redirected Active, not Hepatocellular Genetic: CAR-CD19 T https://ClinicalTrials.gov/
autologous T cells with a chimeric recruiting Carcinoma, et al. cell|genetic: CAR-BCMA T show/NCT03302403
antigen receptor in patients with cell|genetic: CAR-GPC3 T
malignant tumors cell|genetic: CAR-CLD18 T
cell|drug: fludarabine|drug:
cyclophosphamide
31 A clinical research of CAR T cells Not yet Stage III Colorectal Biological: Anti-CEA-CAR T https://ClinicalTrials.gov/
targeting CEA positive colorectal recruiting Cancer|Colorectal show/NCT04513431
cancer (CRC) Cancer Liver Metastasis
32 Study of anti-CEA CAR-T + Not yet Malignant tumor of Biological: anti-CEA CAR-T https://ClinicalTrials.gov/
chemotherapy vs. chemotherapy recruiting pancreas metastatic to cells|drug: gemcitabine/nab show/NCT04037241
alone in patients with CEA+ liver paclitaxel|drug: NLIR+FU/
pancreatic cancer & liver FA|drug: capecitabine
metastases
33 Glypican 3-specific chimeric Recruiting Hepatocellular Genetic: GLYCAR T https://ClinicalTrials.gov/
antigen receptor expressing T Carcinoma cells|drug: cytoxan|drug: show/NCT02905188
cells for hepatocellular carcinoma fludarabine
(GLYCAR)
34 4th generation chimeric antigen Recruiting Advanced Hepatocellular Drug: CAR-GPC3 T cells https://ClinicalTrials.gov/
receptor T cells targeting Carcinoma show/NCT03980288
glypican-3
35 PD-1 antibody expressing CAR-T Unknown PD-1 Antibody|CAR-T Biological: HerinCAR-PD1 https://ClinicalTrials.gov/
cells for EGFR family member status cells|advanced solid cells show/NCT02862028
positive advanced solid tumor tumor
(lung, liver and stomach)
36 Chimeric antigen receptor T cells Recruiting Hepatocellular Biological: CAR-GPC3 T https://ClinicalTrials.gov/
targeting glypican-3 carcinoma cells show/NCT03884751
37 A clinical study in patients with Active, not Hepatic Carcinoma Drug: tumor infiltrating https://ClinicalTrials.gov/
high-risk recurrent primary recruiting lymphocyte show/NCT04538313
hepatocellular carcinoma using
autologous TILs
38 CAR-GPC3 T cells in patients Completed Hepatocellular Genetic: CAR-GPC3 T cells https://ClinicalTrials.gov/
with refractory hepatocellular Carcinoma show/NCT03146234
carcinoma